Lung Cancer 2020 May 24 [Link] Jose Luis Leal, Geoffrey Peters, Marcin Szaumkessel, Trishe Leong, Khashayar Asadi, Gareth Rivalland, Hongdo Do, Clare Senko, Paul L Mitchell, Chai Zi Quing, Alexander Dobrovic, Bibhusal Thapa, Thomas John Abstract Objectives: Gene rearrangements involving NTRK1, NTRK2, NTRK3, ROS1 and ALK have been identified in many types of cancer, including…

Read More

Pathology International 2020 June 15 [Link] Yoshiaki Kinoshita, Makoto Hamasaki, Shinji Matsumoto, Masayo Yoshimura, Ayuko Sato, Tohru Tsujimura, Toshiaki Kamei, Kunimitsu Kawahara, Kazuki Nabeshima Abstract BRCA1-associated protein 1 (BAP1) or methylthioadenosine phosphorylase (MTAP) immunohistochemistry (IHC) or 9p21 fluorescence in situ hybridization (FISH) are useful for the diagnosis of malignant pleural mesothelioma (MPM). However, the effect…

Read More

Diagnostic Cytopathology 2020 May 22 [Link] Kenzo Hiroshima, Di Wu, Shinji Hamakawa, Shingo Tsuruoka, Daisuke Ozaki, Hideki Orikasa, Mizue Hasegawa, Eitetsu Koh, Yasuo Sekine, Yoko Yonemori, Kazuki Nabeshima, Shoutaro Tsuji, Yohei Miyagi, Kohzoh Imai Abstract Background: The specificity and sensitivity of HEG1 for malignant mesothelioma (MM) is high. The use of BAP1/MTAP immunohistochemistry (IHC) is…

Read More

Thoracic Cancer 2020 May 21 [Link] Hossein Taghizadeh, Sabine Zöchbauer-Müller, Robert M Mader, Leonhard Müllauer, Thomas Klikovits, Thomas Bachleitner-Hofmann, Mir A Hoda, Gerald W Prager Abstract Background: Malignant mesothelioma is an aggressive cancer and has a poor prognosis. Here, we analyzed the feasibility, molecular and gender aspects of targeted therapy recommendations for malignant mesothelioma based…

Read More

Oncology Letters 2020 June [Link] Guozun Zhang, Dong-Liang Yang, Guoqi Zheng, Yufei Liang Abstract Malignant peritoneal mesothelioma (MPeM) is an incurable cancer strongly associated with asbestos exposure and characterised by poor prognosis. The aim of the present study was to elucidate the prognostic and predictive value of CD146 and survivin expression in MPeM. Diagnostic biopsies…

Read More

International Immunopharmacology 2020 April 24 [Link] Zhang F, Gong W Abstract OBJECTIVE:Programmed death ligand 1 (PD-L1) has been reported to be connected to prognosis in individuals with malignant pleural mesothelioma (MPM), although there is no consensus based on data from previous studies. Accordingly, this quantitative meta-analysis investigated prognostic and clinicopathological utility of PD-L1 in patients…

Read More

European Journal of Histochemistry 2020 April 16 [Link] Loreto C, Caltabiano R, Graziano ACE, Castorina S, Lombardo C, Filetti V, Vitale E, Rapisarda G, Cardile V, Ledda C, Rapisarda V. Abstract Fluoro-edenite (FE), an asbestiform fiber, is responsible for many respiratory pathologies: chronic obstructive diseases, pleural plaques, fibrosis, and malignant mesothelioma. Macrophage migration inhibitory factor…

Read More

Journal of Thoracic Oncology 2020 March 9 [Link] Salle FG, Le Stang N, Tirode F, Courtiol P, Nicholson AG, Tsao MS, Tazelaar HD, Churg A, Dacic S, Roggli V, Pissaloux D, Maussion C, Moarii M, Beasley MB, Begueret H, Chapel DB, Copin MC, Gibbs AR, Klebe S, Lantuejoul S, Nabeshima K, Vignaud JM, Attanoos R,…

Read More

Lung Cancer 2020 February 12 [Link] Zucali PA, Perrino M, De Vincenzo F, Giordano L, Cordua N, D’Antonio F, Santoro A Abstract OBJECTIVES: Second-line chemotherapy is not a standard of care in patients with malignant pleural mesothelioma (MPM) that progresses after first-line treatment with cisplatin and pemetrexed. In pre-clinical models, the combination of gemcitabine (GEM)…

Read More